An Extension Study of S-606001 in Participants With Late-onset Pompe Disease (LOPD)

The primary purpose of this study is to evaluate the long-term safety and tolerability profile of S-606001 in participants with LOPD. Participants who completed other S-606001 studies (for example, NCT07123155), including participants in a S-606001 study whose allocated arm was terminated by the sponsor and who are willing to participate in this study, will be enrolled globally.

Key Inclusion Criteria: * Participant must be ≥40 kilograms of body weight at the time of signing the informed consent * Participants who previously completed a S-606001 Pompe treatment study, including participants whose assigned treatment arm was terminated by the sponsor Key Exclusion Criteria: * Has a medical condition or any other extenuating circumstance that may, in the opinion of the investigator or medical monitor, pose an undue safety risk to the participant or may compromise his/her ability to comply with or adversely impact protocol requirements * Current enrollment in any other clinical study involving an investigational intervention or any other type of medical research * Participant, if female, is pregnant or breastfeeding at visit 1 * Participant, whether male or female, is planning to conceive a child during the study Note: Other protocol-specified inclusion and exclusion criteria may apply.